DR. DOMINICK IMUNDI GOLIO, M.D.
Medical Practice at Park Ave, New York, NY
License number
New York 236097
Category
Medical Practice
Type
Plastic Surgery
License number
New York ME0087053
Category
Radiology
Type
Plastic and Reconstructive Surgery
License number
New York 236097
Category
Medical Practice
Type
Ophthalmology
Address
Address
935 Park Ave SUITE 1B, New York, NY 10028
Phone
(212) 628-8880
(212) 628-8881 (Fax)
(212) 628-8881 (Fax)
Personal information
See more information about DOMINICK IMUNDI GOLIO at radaris.comName
Address
Phone
155 Country Ridge Rd, Scarsdale, NY 10583
25 Franklin Ave APT 6N, White Plains, NY 10601
27 Richard Ave, Ronkonkoma, NY 11779
35 Barnes Dr, Garnerville, NY 10923
746 Mamaroneck Ave, Mamaroneck, NY 10543
Professional information
See more information about DOMINICK IMUNDI GOLIO at trustoria.com
Dr. Dominick I Golio, New York NY - MD (Doctor of Medicine)
Dr. Dominick I Golio, New York NY - MD (Doctor of Medicine)
Specialties:
Plastic Surgery
Address:
Park Avenue
935 Park Ave SUITE 1B, New York 10028
(212) 628-8880 (Phone), (212) 628-8881 (Fax)
935 Park Ave SUITE 1B, New York 10028
(212) 628-8880 (Phone), (212) 628-8881 (Fax)
Procedures:
Cosmetic Eyelid Surgery, Cosmetic Surgical Procedures, Facial Bone Fracture Repair, Facial Implant Surgery, Jaw Implant Surgery, Nasal Surgery, Neck Lift, Reconstructive Eyelid Surgery, Reconstructive Surgery, Rhinoplasty, Sinus Surgery
Conditions:
Nasolacrimal Duct Obstruction
Awards:
Patient's Choice Award, 2008,2009,
Languages:
English, Spanish
Hospitals:
Park Avenue
935 Park Ave SUITE 1B, New York 10028
Jamaica Hospital Medical Center
8900 Van Wyck Expy, Jamaica 11418
Long Island College Hospital
339 Hicks St, Brooklyn 11201
935 Park Ave SUITE 1B, New York 10028
Jamaica Hospital Medical Center
8900 Van Wyck Expy, Jamaica 11418
Long Island College Hospital
339 Hicks St, Brooklyn 11201
Education:
Medical School
St George's University
Graduated: 1998
New York Medical College
Graduated: 1999
Graduated: 2002
University Of Texas-Md Anderson Cancer Center
Graduated: 2005
University Of Utah Hospital
Graduated: 2006
St George's University
Graduated: 1998
New York Medical College
Graduated: 1999
Graduated: 2002
University Of Texas-Md Anderson Cancer Center
Graduated: 2005
University Of Utah Hospital
Graduated: 2006
Cfo At Medquist
Cfo At Medquist
Location:
Greater New York City Area
Industry:
Hospital & Health Care
Sr Accountant At Louis Dreyfus
Sr Accountant At Louis Dreyfus
Position:
Sr Accountant at Louis Dreyfus
Location:
Greater New York City Area
Industry:
Accounting
Work:
Louis Dreyfus
-
Sr Accountant
Independent Accounting Professional
Independent Accounting Professional
Location:
Greater New York City Area
Industry:
Accounting
Composition And Method Of Treating Lipid Encapsulated Virus Infections
Composition And Method Of Treating Lipid Encapsulated Virus Infections
US Patent:
2011031, Dec 22, 2011
Filed:
Jun 22, 2010
Appl. No.:
12/820862
Inventors:
Dominick Golio - New York NY, US
International Classification:
A61K 36/28, A61P 31/12, A61P 31/22
US Classification:
424737
Abstract:
A method of treating a patient infected with a lipid encapsulated virus by administering to the patient about 1000 mg to about 5000 mg per day of a nutritional supplement having from about 40 to about 80 wt. % L-lysine, from about 20 to about 50 wt. % butylated hydroxytoluene and from about 1 to about 10 wt. % . Administration of the nutritional supplement inhibits ulcer formation resulting from lipid encapsulated virus infections such as herpes simplex I and II infections.
Composition And Method Of Treating Lipid Encapsulated Virus Infections
Composition And Method Of Treating Lipid Encapsulated Virus Infections
US Patent:
8609160, Dec 17, 2013
Filed:
May 21, 2012
Appl. No.:
13/476580
Inventors:
Dominick Golio - New York NY, US
International Classification:
A61K 36/28
US Classification:
424737, 514731, 562562
Abstract:
A method of treating a patient infected with a lipid encapsulated virus by administering to the patient about 1000 mg to about 5000 mg per day of a nutritional supplement having from about 40 to about 80 wt. % L-lysine, from about 20 to about 50 wt. % butylated hydroxytoluene and from about 1 to about 10 wt. %. Administration of the nutritional supplement inhibits ulcer formation resulting from lipid encapsulated virus infections such as herpes simplex I and II infections.